Medical Marijuana (MJNA) AI Stock Analysis

• Market Cap: $1.42M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -18.88%
• EPS Growth: 87.50%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 5,689,450,000
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.03
• Price to Book (P/B): 0.04
• Price to Sales (P/S): 0.14
• P/FCF Ratio: 2.08
• Enterprise Value/Market Cap: 10.58
• Enterprise Value/Revenue: 1.11
• Enterprise Value/Gross Profit: 1.42
• Enterprise Value/Ebitda: 99.63
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Medical Marijuana's financial performance indicates significant challenges, with declining revenues and operational inefficiencies. The lack of technical analysis data and a negative P/E ratio further highlight potential risks. The company's stock remains risky, requiring strategic improvements for better financial health.

Medical Marijuana Business Overview & Revenue Model

Company Description

Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California.

How the Company Makes Money

Medical Marijuana, Inc. generates revenue through multiple streams, primarily from the sale of hemp-derived CBD products. The company operates several subsidiaries that focus on different aspects of the cannabis market, including retail sales, direct selling, and wholesale distribution. Additionally, MJNA leverages strategic partnerships and licensing agreements to expand its product offerings and market reach. The company also invests in research and development to innovate new products and improve existing formulations, which can lead to increased market share and sales. Revenue is further supported by a robust e-commerce platform that allows direct consumer sales, contributing significantly to its earnings.

Medical Marijuana Financial Statement Overview

Summary

Medical Marijuana faces several financial challenges, including declining revenue and persistent net losses. While the balance sheet shows some stability with a solid equity base, the debt level and cash flow volatility highlight ongoing financial risks. The company needs to address its operational inefficiencies to achieve financial stability.

Income Statement

The company's revenue has been declining steadily over the past years, with a significant drop in net income resulting in negative profit margins. The gross profit margin remains positive, but the company struggles with negative EBIT and EBITDA margins, indicating operational challenges.

Balance Sheet

The company maintains a relatively high equity ratio, suggesting a strong equity base compared to its liabilities. However, the increasing debt-to-equity ratio poses a potential risk, and the negative return on equity indicates poor net income performance relative to shareholder equity.

Cash Flow

The company has shown some improvement in operating cash flow, but free cash flow remains volatile with significant fluctuations in recent years. Positive free cash flow in the latest period is a positive sign, but overall cash flow performance remains inconsistent.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.62M	14.91M	16.81M	25.10M	34.12M	46.94M
Gross Profit	10.58M	11.66M	11.25M	18.46M	26.86M	37.73M
EBITDA	151.01K	-73.98K	-4.72M	-14.94M	-4.04M	-95.03M
Net Income	-419.04K	-641.60K	-5.08M	-15.35M	-4.77M	-95.78M
Balance Sheet
Total Assets	67.97M	67.83M	69.55M	68.92M	80.72M	84.32M
Cash, Cash Equivalents and Short-Term Investments	973.83K	1.03M	674.22K	736.51K	5.45M	6.30M
Total Debt	2.94M	2.85M	3.70M	7.65M	4.80M	10.20M
Total Liabilities	17.60M	18.03M	19.63M	14.32M	11.58M	19.00M
Stockholders Equity	50.37M	49.80M	49.92M	54.60M	69.13M	65.32M
Cash Flow
Free Cash Flow	692.49K	977.30K	-6.90M	-17.61M	-4.50M	-95.95M
Operating Cash Flow	692.49K	977.30K	-2.54M	-14.75M	-4.48M	-95.95M
Investing Cash Flow	203.42K	408.58K	-2.67M	6.17M	1.86M	93.17M
Financing Cash Flow	-395.54K	-384.13K	5.15M	3.89M	1.77M	2.87M

Medical Marijuana Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNDL	59 Neutral	$648.65M	―	-8.30%	―	0.70%	15.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLRY	51 Neutral	$1.93B	―	-85.59%	―	2.31%	-726.17%
FLGC	44 Neutral	$12.18M	―	-230.73%	―	-24.10%	38.17%
MJNA	39 Underperform	$1.42M	―	-0.83%	―	-18.88%	87.50%
YCBD	39 Underperform	$10.96M	―	-33.13%	―	-7.80%	90.17%